# CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

> **NCT03706326** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangdong Pharmaceutical University** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Esophageal Cancer

## Interventions

- **BIOLOGICAL:** Anti-MUC1 CAR-T cells
- **BIOLOGICAL:** PD-1 knockout Engineered T cells
- **COMBINATION_PRODUCT:** CAR-T combined with PD-1 Knockout T cells

## Key facts

- **NCT ID:** NCT03706326
- **Lead sponsor:** The First Affiliated Hospital of Guangdong Pharmaceutical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-28
- **Primary completion:** 2021-09-28
- **Final completion:** 2021-09-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706326, "CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03706326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*